Can a common drug slow brain tumors? new study investigates acetadote in GBM
NCT ID NCT07387666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test how Acetadote, a drug that affects cell damage, changes metabolism in people with newly diagnosed glioblastoma. Ten participants will receive Acetadote before surgery, and researchers will use MRI scans and tumor tissue analysis to measure metabolic changes. The goal is to understand if Acetadote can slow tumor growth, not to provide a cure or treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-••••
Contact
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- Targeted antibody may boost brain cancer treatment after incomplete surgery
- Spinal fluid DNA test could personalize brain cancer therapy
- Tailored radiation blasts brain tumors where They're most likely to return
- Personalized vaccine takes aim at recurrent brain tumors